Vivanza Biosciences Ltd Directors Report

To,

The Members,

Vivanza Biosciences Limited

Your directors are pleased to present the 44th (Forty-Fourth) Annual Report of your company together with the Audited Financial Statement of your company for the financial year ended 31st March, 2026.

1. FINANCIAL SUMMARY/HIGHLIGHTS OF PERFORMANCE OF THE COMPANY:

(Rs.in Lacs)

	Standalone	Standalone	Consolidated	Consolidated
Particulars	Year ended 31/03/2026	Year ended 31/03/2025	Year ended 31/03/2026	Year ended 31/03/2025
I. Total Revenue	11,234.04	297.74	11,602.21	748.48
II. Total Expenditure	11,182.25	367.10	11,547.84	815.05
III. Profit/(Loss) Before Tax (I-II)	51.79	(69.36)	54.37	(66.57)
IV. Provision for Taxation	14.29	0.15	14.93	0.84
V. Profit/(Loss) After Tax (III-IV)	37.50	(69.51)	39.44	(67.41)

2. PERFORMANCE AND STATE OF AFFAIRS OF THE COMPANY:

During the year under review, the Company has earned revenue of Rs. 11,234.04 lacs. The Board of Directors of the Company is continually working to drive the Companys growth.

3. CHANGE IN NATURE OF BUSINESS:

During the financial year, there have not been any changes in the nature of business of the Company.

4. DIVIDEND:

The Board of Directors has not recommended any dividend during the year under review. In terms of Regulation 43A of the Listing Regulations, the Board of Directors of the Company has adopted a Dividend Distribution Policy, which sets out the parameters and circumstances to be considered by the Board in determining the distribution of dividend to its shareholders. These parameters include Companys distributable profits, utilization and future plans, capital expenditure and such other factors as may be considered by the Board for optimum dividend pay-outs. The Dividend Distribution Policy is available on the Companys website atwww.vivanzabiosciences.com

5. TRANSFER TO RESERVE:

Reserves & Surplus at the end of the year stood at Rs. 39,54,000 as compared to Rs. 2,04,000 at the beginning of the year.

6. SHARE CAPITAL:

At present, the Company has only one class of shares – equity shares with face value of Rs.1/- each.

AUTHORIZED SHARE CAPITALThe Authorized Share Capital of the Company is Rs.4,00,00,000/- divided into 4,00,00,000 equity shares of Rs.1/- each.

ISSUED, SUBSCRIBED AND PAID-UP SHARE CAPITAL:

The issued, subscribed paid up share capital of the company as on March 31, 2026 is Rs. 4,00,00,000/- divided into 4,00,00,000 equity shares of Rs.1/- each.

7. MATERIAL CHANGES AND COMMITMENTS IF ANY, AFFECTING THE FINANCIAL POSITION OF THE COMPANY WHICH HAVE OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR OF THE COMPANY TO WHICH THE FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT

No Material changes have occurred during the year which shall affect the Financial position of the Company.

8. PERFORMANCE AND FINANCIAL POSITION OF EACH OF THE SUBSIDIARIES, ASSOCIATES, AND JOINT VENTURE COMPANIES

No Company has become or ceased to be subsidiary/Joint venture/Associate Company of the Company during the year. However, the Company has one wholly owned subsidiary Company i.e.

Sr. No	Name of Subsidiary	Status
1.	Vivanza Lifesciences Private Limited	Wholly Owned Subsidiary

Form AOC-1 in this regard is attached at the end of the financial statements as Annexure-A.

9. DEPOSITS

The Company has neither accepted nor renewed any deposit within the meaning of the Companies (Acceptance of Deposits) Rules, 2014.

10. DISCLOSURE REGARDING ISSUE OF EMPLOYEE STOCK OPTION:

Company has not issued any Employee Stock Option during the year.

11. ANNUAL RETURN ON WEBSITE

Draft of Annual Return as on 31st March, 2026 in Form MGT-7 is available on the website of the Company www.vivanzabiosciences.com.

12. DISCLOSURE REGARDING ISSUE OF SWEAT EQUITY SHARES

During the year, the Company has not issued Sweat Equity shares. Hence, details as per Rule 8(13) of the Companies (Share Capital and Debentures) Rule, 2014 are not reported yet.

13. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The Company continues to accord high priority to the conservation of energy and natural resources as part of its operational and sustainability objectives.

The Company continued its efforts towards technology absorption through the adoption of advanced manufacturing technologies, automation and process improvement initiatives aimed at enhancing manufacturing efficiency, product quality and productivity.

The details foreign exchange earnings and outgo are as under.

Particulars	2025-26	2024-25
Foreign Exchange Earning	668.36	120.96
Foreign Exchange Outgo	---	---

14. CORPORATE SOCIAL RESPONSIBILITY (CSR)

Corporate Social Responsibility (CSR) is not applicable to the Company during the year.

15. DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Details of Appointment/resignation of Directors and Key Managerial Personnel

Mr Sarang Bharathbhai Pathak (DIN: 02663344) was appointed as an Additional Director at a Board Meeting held on 30th August, 2025, as a Non-Executive Non-Independent Director, and upon receipt of shareholders approval the appointment was approved at the Annual General Meeting held on 25th September, 2025.

Mr. Hitesh Rijwani (DIN:11030634) was appointed as an Additional Director at a Board Meeting held on 12th May, 2025 as a Non-Executive Independent Director for the period of five years and upon receipt of shareholders approval the appointment was approved by Member at Annual General Meeting held on 25th September,2025.

Mr. H A Parikh has resigned from the position of Non- Executive Director w.e.f. 17th March, 2026.

Mr. Aagam Shah has resigned from the position of Non- Executive Independent Director w.e.f. 11th May, 2025.

Ms. Siddhi Shah has Resigned from the post of Company Secretary and Compliance Officer w.e.f 26th September, 2025.

Mr. Chaitra Arora has been appointed as a Company Secretary and Compliance Officer w.e.f. 11th November, 2025.

EVENTS OCCURRING AFTER THE CLOSER OF THE FINANCIAL YEAR

Mr. H. A. Parikh has been appointed as a Non- Executive Non-independent Additional Director w.e.f. 18th June, 2026.

Mr. Chaitra Arora has Resign from the post of Company Secretary and Compliance Officer w.e.f. 30th April, 2026.

Mr. Vishal Katarmal has been appointed as aCompany Secretary and Compliance Officer w.e.f. 09th July, 2026.

RETIRE BY ROTATION:

Pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of your Company, Mr. Jayendra Mehta (DIN: 08210602), Managing Director of the Company, is liable to retire by rotation at the ensuing AGM and, being eligible, has offered themselves for reappointment

Appropriate resolutions for their re-appointment are being placed for your approval at the ensuing AGM.

Your Directors recommend their re-appointment as the Managing Director and Executive Director, respectively of your Company.

B. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SECTION 149(6) OF THE ACT

The Board of Directors hereby declares that all the independent directors duly appointed by the Company have given the declaration and they meet the criteria of independence as provided under Section 149(6) of the Act.

C. STATEMENT WITH REGARDS TO INTEGRITY, EXPERTISE AND EXPERIENCE OF INDEPENDENT DIRECTORS

Your Directors are of the opinion that the Independent Directors of the Company are of high integrity and suitable expertise as well as experience (including proficiency)

D. FORMAL ANNUAL EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17 and Regulation 25 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a structured questionnaire was prepared after taking into consideration of the various aspects of the Boards functioning, Composition of the Board and Committees, culture, execution and performance of specific duties, obligation and governance. The performance evaluation of the Independent Directors was completed.

During the financial year under review, the Independent Directors met on 12th May, 2025 inter alia, to discuss:

- Performance evaluation of Non-Independent Directors and Board of Directors as a whole;

- Performance evaluation of the Chairman of the Company;

- Evaluation of the quality of flow of information between the Management and Board for effective performance by the Board.

The Board of Directors expressed their satisfaction with the evaluation process.

E. POLICY ON DIRECTORS APPOINTMENT AND REMUNERATION

The Company has a Nomination and Remuneration Committee. The Committee reviews and recommends to the Board of Directors about remuneration for Directors and Key Managerial Personnel and other employees up to one level below Key Managerial Personnel. The Company does not pay any remuneration to the Non-Executive Directors of the Company other than a sitting fee for attending the Meetings of the Board of Directors and Committees of the Board. Remuneration to Executive Directors is governed by the relevant provisions of the Act and approvals.

The Company has devised the Nomination and Remuneration Policy for the appointment, re-appointment and remuneration of Directors, Key Managerial Personnel and Senior Management Personnel. All the appointment, re-appointment and remuneration of Directors, Key Managerial Personnel and Senior Management Personnel are as per the Nomination and Remuneration Policy of the company.

16. MEETINGS

A calendar of Meetings is prepared and circulated in advance to the Directors. During this year, Six Board meetings were held, which are as follows. 12.05.2025, 13.08.2025, 30.08.2025, 01.09.2025, 11.11.2025, 12.02.2026.

The intervening gap between the Meetings was within the period prescribed under The Act and The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015[LODR].

POSTAL BALLOT:

During the Financial Year 2025-26, the following special resolutions were passed by the Company through postal ballot notice dated November 11, 2025 and approved by the shareholders on December 06, 2025:

Sr. No.	Special Resolution	No of votes polled	No. and % of votes in favour	No. and % of votes against
1.	Alteration of the object clause of the memorandum of association of the company	51,11,539	51,06,561 (99.90%)	4,978 (0.10%)

The following actions were conducted pursuant to the approval of the Board and in compliance with the provisions of the Act and MCA Circulars:

i. Mr. Chintan K. Patel (Membership No: A31987), Proprietor of Chintan K. Patel, Practising Company Secretary (COP No. 11959), was appointed as the Scrutinizer for conducting the Postal Ballot only through Remote E-voting in a fair and transparent manner;

ii. The Company availed the services of M/s. Purva Sharegistry (India) Private Limited for providing the Remote E-voting facility to the Members;

iii. A newspaper advertisement as required under the Act and the MCA Circulars was published on November 15, 2025, in the English and Gujarati editions of Indian Express and Financial Express, respectively;

iv. The Remote E-voting period commenced at 9:00 a.m. (IST) on Monday, November 17th, 2025 and ended at 5:00 p.m. (IST) on Tuesday, December 16th, 2025

17. DETAILS OF ESTABLISHMENT OF VIGIL MECHANISM FOR DIRECTORS AND EMPLOYEES

The Company has established a vigil mechanism and accordingly framed a Whistle Blower Policy. The policy enables the employees to report to the management instances of unethical behaviour, actual or suspected fraud or violation of Companys Code of Conduct.

Further the mechanism adopted by the Company encourages the Whistle Blower to report genuine concerns or grievances and provide for adequate safe guards against victimization of Whistle Blower who avails of such mechanism and also provides for direct access to the Chairman of the Audit Committee, in exceptional cases.

The functioning of vigil mechanism is reviewed by the Audit Committee from time to time. None of the Whistle blowers has been denied access to the Audit Committee of the Board. The Whistle Blower Policy of the Company is available on the website of the Company www.vivanzabiosciences.com.

18. PARTICULARS OF LOANS GIVEN, GUARANTEES GIVEN, INVESTMENTS MADE AND SECURITIES PROVIDED

Details of Loans, Guarantees and Investments covered under the provisions of Section 186 of the Companies Act, 2013 are given in the Notes to the Financial Statements.

19. PARTICULARS OF CONTRACTS OR ARRANGEMENTS WITH RELATED PARTIES

Particulars of contracts or arrangements with related parties in Form AOC-2 are enclosed as per Annexure-B.

20. MANAGERIAL REMUNERATION

Disclosures pursuant to Section 197(12) of The Companies Act, 2013 read with Rule 5(1), 5(2) and 5(3) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are enclosed herewith as per Annexure-D.

21. AUDITORS

- INTERNAL AUDITOR

Section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 and based on the recommendations made by the Audit Committee M/s. Dharti Shah & Co Chartered Accountants, Ahmedabad has been appointed as the Internal Auditors for carrying out the Internal Audit of the company for the FY 2026-2027.

- STATUTORY AUDITORS

M/s. Shivam Soni & Co., Chartered Accountant have been appointed as Statutory Auditors of the Company from the conclusion of the 40th Annual General Meeting to hold office upto the conclusion of 46th Annual General Meeting.

- SECRETARIAL AUDITORS

M/s. Chintan Patel & Associates, Practicing Company Secretaries, Ahmedabad, Gujarat, were appointed as Secretarial Auditors, to carry out Secretarial Audit of the Company as per provisions of Section 204 of The Companies Act, 2013 and issue of Annual Secretarial Compliance certificate pursuant to Regulation 24A of LODR. The Secretarial Audit Report have been annexed to this Report as per Annual Annexure E

- Explanation or Comments on disqualifications, reservations, adverse remarks or disclaimers in the Auditors Reports;

STATUTORY AUDITORS REPORT AND SECRETARIAL AUDIT REPORT

Neither the Statutory Auditors nor the Secretarial Auditors of the Company in their respective draft reports, have made any qualifications, reservations, adverse remarks or disclaimers. Accordingly, no explanations/ comments thereon are required to be furnished.

22. CORPORATE GOVERNANCE REPORT

As per Regulation 15(2) of the SEBI Listing Regulations, compliance with the corporate governance provisions as specified in regulation 17 to 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V, shall not apply in respect of the listed entity having paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty five crore, as on the last day of the previous financial year. At present, the Company is not required to comply with Corporate Governance regulations as none of the above referred limits have been triggered.

23. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

A report on Management Discussion and Analysis, as required in terms of Regulation 34(2) of LODR forms part of this Report. It deals with the Business Operations and Financial Performance, Research & Development Expansion & Diversification, Risk Management, Marketing Strategy, Safety & Environment, Human Resource Development, etc. enclosed as per Annexure-H

24. RISK MANAGEMENT

The Company is aware of the risks associated with the business. It regularly analyses and takes corrective actions for managing/mitigating the same.

The Company has framed a formal Risk Management Framework for risk assessment and risk minimization which is periodically reviewed to ensure smooth operation and effective management control. The Audit Committee also reviews the adequacy of the risk management framework of the Company, the key risks associated with the business and measure and steps in place to minimize the same.

25. DIRECTORS RESPONSIBILITY STATEMENT

As stipulated in Section 134(3)(c) read with sub section 5 of the Companies Act, 2013, Directors subscribe to the "Directors Responsibility Statement" and confirm that:

a) In preparation of annual accounts for the year ended 31st March, 2026, the applicable accounting standards have been followed and that no material departures have been made from the same;

b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for that year;

c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The Directors had prepared the annual accounts for the year ended 31st March, 2026 on going concern basis.

e) The Directors had laid down the internal financial controls to be followed by the Company and that such Internal Financial Controls are adequate and were operating effectively; and

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

26. DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company is committed to providing a safe, respectful and equal-opportunity workplace and follows a zero-tolerance policy towards sexual harassment. In line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("POSH Act") and the rules made thereunder, the Company has adopted a comprehensive POSH Policy covering all employees, including permanent, temporary, contractual, and trainees. The policy clearly sets out procedures for prevention, prohibition, and redressal of complaints, along with guidelines for investigation and resolution.

In accordance with the provisions of the POSH Act, the Company has duly constituted Internal Complaints Committees (ICCs), including an external member, at the Corporate Office as well as at plant. The ICC is entrusted with the responsibility of addressing and resolving complaints in a fair, impartial, and timely manner. Your Company also conducts regular awareness and sensitization programmes, including employee induction sessions, to promote understanding of the POSH framework and encourage a respectful work culture.

Details of Sexual Harassment Complaints received during the year under review are as follows:

Particulars	Number of Complaints
No. of Complaints of Sexual Harassment received in the year	NIL
No. of Complaints disposed off during the year	NIL
No. of cases pending for more than ninety days	NIL

27. DIRECTORS TRAINING & FAMILIARIZATION

The Directors are regularly informed during the meetings of the Board and the Committees, of the activities of the Company, its operations and issues faced by the Engineering Industry. Considering the long association of the Directors with the Company and their seniority and expertise in their respective areas of specialization and knowledge of the engineering industry, their training and familiarization were conducted in the below mentioned areas:

- The Roles, Rights, Responsibilities and Duties of Independent Directors

- Business Development Strategy and Plans

- Changes brought in by the introduction of the Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015

- Changes in the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

28. AUDIT COMMITTEE

The Audit Committee of the Board consists of Two Independent and One Executive Non-Independent Director. The composition, role, terms of reference as well as power of the Audit Committee are in accordance with the provisions of Regulation 18 of LODR and Section 177 of The Act and Rules framed thereunder.

The details of all related party transactions are placed periodically before the Audit Committee. All the recommendations made by the Audit Committee were accepted by the Board. The Company has in place a Vigil Mechanism; details of which are available on the Companys website.

The Audit Committee comprises of the following Members as on March 31, 2026-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-Executive Independent Directorw.e.f 12.05.2025

There were 4 (Four) Meetings of the Audit Committee of the Board of Directors held during the Financial Year 2025-26, (i.e. 12th May, 2025, 13th August, 2025, 11th November, 2025, 12th February, 2026).

The Statutory Auditors and Chief Financial Officer attend the Audit Committee Meetings as Invitees. The Company Secretary and Compliance Officer acts as Secretary to the Audit Committee. The Audit Committee has made observations and recommendations to the Board of Directors, which have been noted and accepted by the Board.

During the Financial Year 2025-26, all recommendations made by the Audit Committee to the Board of Directors were accepted by the Board and there were no instances where the recommendations were not accepted.

29. NOMINATION AND REMUNERATION COMMITTEE

In compliance with Section 178 of The Act, Your Company has in place a "Nomination and Remuneration Committee". The powers, role and terms of reference of the Nomination and Remuneration Committee cover the areas as contemplated under Regulation 19 of LODR and Section 178 of The Act, and Rules and Regulations, framed thereunder, besides other terms as may be referred by the Board of Directors.

The Nomination and Remuneration Committee comprises of the following Members as on March 31st, 2026:-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-Executive, Independent Director w.e.f 12.05.2025

There was 3 (Three) Meetings of the Nomination and Remuneration Committee of the Board of Directors held during the Financial Year 2025-26 (i.e., on 12th May 2025, 30th August,2025, 11th November, 2025 ).

30. STAKEHOLDERS RELATIONSHIP COMMITTEE:

Pursuant to the provisions of Section 178 of the Companies Act, 2013, your Company has constituted a Stakeholders Relationship Committee of the Board of Directors, comprising of the following Members during the Financial Year 2025-26:-

Name	Designation	Category
Ms. Rina Kumari	Chairman	Non-Executive, Independent Director
Mr. Hitesh Rijwani	Member	Non-Executive, Independent Director
Mr. Jayendra Mehta	Member	Executive Director

*Mr. Hitesh Rijwani has been appointed as Non-Executive, Independent Director w.e.f 12.05.2025

During the Financial Year 2025-2026, 4 (Four) Meeting of the Stakeholders Relationship Committee was held, (i.e., on 15.05.2025, 11.08.2025, 20.11.2025 and 10.01.2026)

31. SECRETARIAL STANDARDS

During the year under Report, the Company has complied with the applicable provisions of Secretarial Standards as issued and notified by The Institute of Company Secretaries of India and approved by the Central Government.

32. INTERNAL CONTROL SYSTEM

Your company maintains a robust system of internal controls designed to safeguard all assets from unauthorized use or misappropriation. Every transaction undergoes stringent processes to ensure proper authorization, accurate recording, and precise reporting. Our internal controls are fortified by a comprehensive program of both internal and external audits, complemented by regular management reviews. These audits ensure the accuracy of financial and operational records, supporting reliable financial reporting and reinforcing accountability for asset stewardship.

The Audit Committee plays a pivotal role in governance, overseeing the effectiveness of our internal controls and compliance initiatives. It reviews audit performance and ensures alignment with regulatory standards.

In the sincere judgment of the Board of Directors and our senior management, our internal control framework is sound, functioning efficiently, and fully capable of supporting the companys operational and reporting objectives.

33. SHAREHOLDERS DISPUTE RESOLUTION MECHANISM:

SEBI vide circular July 31, 2023 and subsequent circular dated December 20, 2023, read with Master Circular dated August 11, 2023, has specified that a shareholder shall first take up his/her/their grievance with the listed entity/RTA by lodging a complaint directly with the concerned listed entity/RTA and if the grievance is not redressed satisfactorily, the shareholder may, in accordance with the SCORES guidelines, escalate the same through the SCORES Portal in accordance with the process laid out therein. Only after exhausting all available options for resolution of the grievance, if the shareholder is not satisfied with the outcome, he/she/ they can initiate dispute resolution through the Online Dispute Resolution ("ODR") Portal. Shareholders are requested to take note of the same.

34. SUSPENSION OF TRADING

The equity shares of the Company have been listed and actively traded on the Main Board of Bombay Stock Exchange (BSE) Limited. There was no occasion on which the equity shares of the Company have been suspended for trading during the FY 2025-2026.

35. REPORTING OF FRAUDS

During the year under review, none of the Auditors have reported any instances of fraud committed in the Company by its officers or employees to the Audit Committee, as required under Section 143 (12) of the Act.

36. MATERNITY BENEFITS

Your Company complies with the provisions of the Maternity Benefit Act, 1961, and provides Maternity Benefits to eligible women employees. Adequate facilities and support are provided in line with statutory requirements.

37. LISTING FEES:

The Company affirms that the annual listing fees for the year 2025-2026 to The Bombay Stock Exchange Limited have been duly paid.

38. AUDIT TRAIL APPLICABILITY (AUDIT AND AUDITORS) RULES, 2014 – RULE 11 OF THE COMPANIES ACT, 2013

The Company had used accounting software for maintaining its books of account for the financial year ended March 31st, 2026, which has a feature of recording audit trail (edit log) facility, and the same has operated throughout the year for all relevant transactions recorded in the software.

39. NO APPLICATION/ PROCEEDING UNDER IBC

Neither any application is made, nor any proceeding is pending under the Insolvency and Bankruptcy Code, 2016 (IBC) during the year under review, and accordingly the Company has no information to offer in this regard

40. WEBSITE DISCLOSURES:

In compliance with the applicable provisions of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company maintains a functional website www.vivanzabiosciences.comcontaining details of its business activities, financial information, statutory disclosures, policies, codes, notices, annual reports and other investor-related information

41. CAUTIONARY STATEMENT:

Statements in the Boards Report and the Management Discussion & Analysis describing the Companys objectives, expectations or forecasts may be forward-looking within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the Companys operations include global and domestic demand and supply conditions affecting selling prices of finished goods, input availability and prices, changes in government regulations, tax laws, economic developments within the country and other factors such as litigation and industrial relations.

42. ACKNOWLEDGEMENTS

Your Directors wish to place on record sincere appreciation for the support and co-operation received from various Central and State Government Departments, organizations and agencies. Your Directors also gratefully acknowledge all stakeholders of your Company, viz., Shareholders, customers, dealers, vendors, banks and other business partners for excellent support received from them during the Financial Year under review. Your Directors also express their warm appreciation to all the employees of the Company for their unstinted commitment and continued contribution to the growth of your Company.

Place: Ahmedabad

Date: August 17, 2026

For and on behalf of the Board

For, Vivanza Biosciences Limited

Sd/-

Jayendra Mehta

Managing Director

DIN:08210602

Sd/-

Sarang Pathak

Director

DIN:02663344